Product Details
Place of Origin: China
Brand Name: Hongbaiyi
Certification: COA, HPLC MR
Model Number: HBY-Reta
Document: Product Brochure PDF
Payment & Shipping Terms
Minimum Order Quantity: 5 boxes
Price: Negotiable
Packaging Details: 5mg/vial, 10vials/Box
Delivery Time: 3~5 days, upon recepient of payment
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 5000 boxes per month
Product Name: |
RETA (LY-3437943) 5mg For Sale |
Appearance: |
White Lyophilized Powder |
CAS No: |
2381089-83-2 |
Purity: |
≥99% Pure (LC-MS) |
Molecular Formula: |
C₂₂₃H₃₄₃F₃N₄₆O₇₀ |
MW: |
4845.44 |
Specification: |
5mg/vial, 10vials/box |
MOQ: |
5 Boxes |
Other Names: |
LY-3437943, NOP2Y096GV, ChEMBL5095485 |
Storage: |
Keep In Dark Place,Inert Atmosphere,Store In Freez |
Product Name: |
RETA (LY-3437943) 5mg For Sale |
Appearance: |
White Lyophilized Powder |
CAS No: |
2381089-83-2 |
Purity: |
≥99% Pure (LC-MS) |
Molecular Formula: |
C₂₂₃H₃₄₃F₃N₄₆O₇₀ |
MW: |
4845.44 |
Specification: |
5mg/vial, 10vials/box |
MOQ: |
5 Boxes |
Other Names: |
LY-3437943, NOP2Y096GV, ChEMBL5095485 |
Storage: |
Keep In Dark Place,Inert Atmosphere,Store In Freez |
99% Pure Reta (LY-3437943) 5mg Vial Peptide Treatment Of Obesity
Product Details of Reta (LY-3437943) 5mg Vial Peptide
|
Product Name |
Reta (LY-3437943) 5mg Vial Peptide |
|
Appearance |
White powder |
|
Specification |
5mg/vial, 10vials/Box |
|
Purity |
99.1% |
|
Test |
HPLC |
|
CAS |
2381089-83-2 |
|
MF |
C₂₂₃H₃₄₃F₃N₄₆O₇₀ |
|
Storage |
Keep in a Dark Place, Inert Atmosphere, Store in Freez |
What is Reta?
Reta is a synthetic triple agonist peptide that activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.
Reta is currently in Phase 3 clinical trials. It has been shown to be safe and effective in reducing body weight and improving blood sugar control in patients with obesity and type 2 diabetes.
Reta is generally well-tolerated, with the most common side effects being mild and transient gastrointestinal disturbances.
Reta has the potential to be a valuable new treatment option for obesity and type 2 diabetes. It is a single-agent therapy that is effective in reducing body weight and improving blood sugar control, with a favorable safety profile.
Reta is a synthetic triple agonist peptide that activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is being developed by Eli Lilly and Company for the treatment of obesity and type 2 diabetes.
Reta works by activating these receptors, which leads to a number of effects that can help to improve weight loss and blood sugar control. For example, Reta can:
Mounjaro (tirzepatide) v.s. reta
Mounjaro (tirzepatide) and reta are both injectable medications that are being developed for the treatment of obesity and type 2 diabetes. However, there are some key differences between the two medications.
Mounjaro is a dual agonist peptide that activates the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Reta is a triple agonist peptide that activates the GLP-1, GIP, and glucagon receptors.
This means that reta has an additional effect on the glucagon receptor, which is a hormone that is responsible for raising blood sugar levels. By blocking the glucagon receptor, reta can help to further lower blood sugar levels.
Another difference between the two medications is the frequency of administration. Mounjaro is administered once weekly, while reta is still under development and the frequency of administration has not yet been finalized.
In terms of clinical data, both Mounjaro and reta have shown promising results in reducing body weight and improving blood sugar control. However, reta has shown to be slightly more effective than Mounjaro in terms of weight loss.
Overall, both Mounjaro and reta are promising new medications for the treatment of obesity and type 2 diabetes. More research is needed to compare the two medications head-to-head, but reta has the potential to be a more effective treatment option for some patients.
Please note that I am not a medical professional and this information should not be taken as medical advice. If you are considering using Mounjaro or reta, please speak to your doctor first.
What are the doses of reta?
Reta is still under development and the final dosing regimen has not yet been finalized. However, in Phase 2 clinical trials, reta was administered once weekly at doses of 1 mg, 4 mg, 8 mg, or 12 mg.
In Phase 3 clinical trials, reta is being administered once weekly at doses of 1 mg, 4 mg, 8 mg, and 12 mg. However, the final dosing regimen for Phase 3 will be determined based on the results of these trials.
It is important to note that reta is a prescription medication and should only be used under the supervision of a doctor. Your doctor will determine the best dose of reta for you based on your individual needs and medical history.
Please note that I am not a medical professional and this information should not be taken as medical advice. If you have any questions about reta, please speak to your doctor.
